`
`________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`________________
`
`AMNEAL PHARMACEUTICALS LLC, PAR PHARMACEUTICAL, INC. and
`WOCKHARDT BIO AG,
`
`Petitioners,
`
`v.
`
`JAZZ PHARMACEUTICALS, INC.
`
`Patent Owner
`
`________________
`
`Case IPR2015-005541
`Patent 7,668,730
`________________
`
`SUPPLEMENTAL DECLARATION OF
`JOSEPH T. DIPIRO, PHARM.D.
`
`
`
`
`
`
`
`
`
`
`1 Case IPR2015-01818 has been joined with this proceeding.
`
`
`
`JAZZ EXHIBIT 2059
`Amneal Pharms. et al. (Petitioners) v. Jazz Pharms., Inc. (Patent Owner)
`Case IPR2015-00554
`
`Page 1 of 3
`
`
`
`
`
`I, Joseph T. DiPiro, Pharm.D., hereby declare and state as follows:
`
`1.
`
`I submit this supplemental declaration on behalf of Jazz
`
`Pharmaceuticals, Inc. (“Jazz”), Patent Owner of U.S. Patent No. 7,668,730 (the
`
`“’730 patent”) in connection with this inter partes review (“IPR”), Case IPR2015-
`
`00554.
`
`2.
`
`I have reviewed the deposition testimony of Dr. Glenn A. Van
`
`Buskirk submitted as Exhibit 2054 in this IPR.
`
`3.
`
`Dr. Van Buskirk’s testimony is consistent with my opinion that a
`
`POSA would not be scanning the Federal Register regularly for notices of advisory
`
`committee meetings (see, e.g., Ex. 2046 ¶ 53) and that only those with skill
`
`exceeding that of a POSA would have a need or motivation to thoroughly read the
`
`Federal Register, specifically to find meeting announcements, and even more
`
`specifically to search for announcements that contain information concerning the
`
`distribution, safety, and abuse of drugs that have not been approved (see, e.g., id. ¶
`
`54). See also id. ¶ 56.
`
`4.
`
`In my opinion, Dr. Van Buskirk’s testimony is consistent with the
`
`actions of a POSA.
`
`
`
`
`
`
`
`
`
`Page 2 of 3
`
`
`
`
`
`
`
`
`
`
`Executed this 30th day of November 2015. I declare under penalty of perjury
`
`that the foregoing is true and correct.
`
`
`
`
`
`
`
`
`
`
`________________________________
`
`
`Joseph T. DiPiro, Pharm.D.
`
`
`
`
`- 2 -
`
`Page 3 of 3